Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company specializing in the development of oncology drug candidates, with a focus on addressing highly resistant tumors and viral infections. Its lead candidate, Annamycin, is a next-generation anthracycline designed to treat relapsed or refractory acute myeloid leukemia (AML) while minimizing cardiotoxicity. Another key drug, WP1066, is an immuno-stimulating STAT3 inhibitor currently in Phase I trials for brain tumors, pancreatic cancer, and AML. Additionally, Moleculin is developing WP1220, which has completed Phase 1 trials for cutaneous T-cell lymphoma, WP1234 for pancreatic cancer, and WP1732 for various cancers including AML. The company is also advancing WP1122, a metabolism/glycosylation inhibitor for cancer and viral treatments. Moleculin has established collaborations with several prominent research institutions, including The University of Texas MD Anderson Cancer Center and Emory University, to further its drug development efforts. Founded in 2015 and headquartered in Houston, Texas, Moleculin aims to innovate in cancer treatment through its diverse portfolio of drug candidates.
AnnaMed is a company that operates in two distinct sectors: dental services and pharmaceutical development. In the dental field, AnnaMed offers a range of services including orthodontics, implants, prosthetics, and endodontics, catering to diverse patient needs. On the pharmaceutical side, the company is developing Annamycin, a clinical-stage drug aimed at treating acute myeloid leukemia. This medication is designed to help patients manage their pain and improve recovery outcomes related to acute cancer conditions. Through its dual focus, AnnaMed seeks to enhance both oral health and cancer treatment options for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.